argenx NV ADR Cash Flow Conversion Efficiency
argenx NV ADR cash flow conversion efficiency. Based on the latest financial reports, argenx NV ADR (ARGX) has a cash flow conversion efficiency ratio of 0.089x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($751.74 Million) by net assets ($8.42 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of argenx NV ADR (2011–2025)
Cash flow conversion efficiency of argenx NV ADR from 2011 to 2025. This chart illustrates how argenx NV ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest argenx NV ADR stock price today for real-time trading data and today's change.
argenx NV ADR Cash Flow Conversion Ratio Explained
argenx NV ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
argenx NV ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of argenx NV ADR ranked by their cash flow conversion efficiency. Also see argenx NV ADR market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ING Groep N.V
MX:INGN
|
N/A |
|
Hess Corporation
NYSE:HES
|
0.113x |
|
Adani Ports and Special Economic Zone Limited
NSE:ADANIPORTS
|
0.096x |
|
Nu Holdings Ltd.
F:M1Z
|
0.073x |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
0.100x |
|
Ambev SA ADR
NYSE:ABEV
|
0.035x |
|
HOLCIM NEW(U.ADR)1/5/SF2
F:HLB
|
N/A |
|
BASF SE
F:BASA
|
0.106x |
Annual Cash Flow Conversion Efficiency for argenx NV ADR (2011–2025)
The table below shows the annual cash flow conversion efficiency of argenx NV ADR from 2011 to 2025. Review ARGX cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.32 Billion | $850.49 Million | 0.116x | +871.70% |
| 2024-12-31 | $5.50 Billion | $-82.75 Million | -0.015x | +85.33% |
| 2023-12-31 | $4.10 Billion | $-420.33 Million | -0.103x | +66.55% |
| 2022-12-31 | $2.81 Billion | $-862.81 Million | -0.307x | -28.06% |
| 2021-12-31 | $2.53 Billion | $-606.81 Million | -0.239x | -0.60% |
| 2020-12-31 | $1.67 Billion | $-398.46 Million | -0.238x | -285.30% |
| 2019-12-31 | $1.18 Billion | $151.63 Million | 0.128x | +228.46% |
| 2018-12-31 | $615.87 Million | $-61.59 Million | -0.100x | +5.62% |
| 2017-12-31 | $413.81 Million | $-43.84 Million | -0.106x | -163.35% |
| 2016-12-31 | $66.65 Million | $11.15 Million | 0.167x | +144.93% |
| 2015-12-31 | $40.82 Million | $-15.19 Million | -0.372x | -192.85% |
| 2014-12-31 | $50.08 Million | $-6.37 Million | -0.127x | +58.24% |
| 2013-12-31 | $29.97 Million | $-9.12 Million | -0.304x | +54.29% |
| 2012-12-31 | $16.65 Million | $-11.09 Million | -0.666x | -366.23% |
| 2011-12-31 | $27.90 Million | $-3.98 Million | -0.143x | -- |
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more